1 / 23

Economic evaluation of MRC/BHF Heart Protection Study

Economic evaluation of MRC/BHF Heart Protection Study. Heart Protection Study Collaborative Group University of Oxford UK. HPS: Eligibility criteria. Increased risk of CHD death due to prior disease: Myocardial infarction or other CHD; Occlusive disease of non-coronary arteries; or

bien
Download Presentation

Economic evaluation of MRC/BHF Heart Protection Study

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Economic evaluation of MRC/BHF Heart Protection Study Heart Protection Study Collaborative GroupUniversity of Oxford UK

  2. HPS: Eligibility criteria • Increased risk of CHD death due to prior disease: • Myocardial infarction or other CHD; • Occlusive disease of non-coronary arteries; or • Diabetes mellitus or treated hypertension • Age 40-80 years • Total cholesterol  3.5 mmol/l ( 135mg/dl) • Statin or vitamins not considered clearly indicated or contraindicated by patient’s own doctors

  3. Cost-effectiveness analysis of allocation to 40mg daily simvastatin • Based on within trial period only (mean 5 years) • Costs for UK National Health Service (2001) • Cost-effectiveness analyses undertaken: • per major vascular event* avoided • per vascular death avoided • overall and in subgroups at differing absolute risk • *first or subsequent heart attack, stroke or revascularisation following randomisation

  4. Major vascular events (MVE) and vascular deaths per 1000 patients

  5. HPS: Methods of calculating costs • Costs included • Study simvastatin (40mg daily at £1/day) and any non-study statin • Hospitalisations for all major and other vascular events • Costs excluded • Non-statin drugs • Hospitalisations for non-vascular events (no significant differences between groups) • Primary and social care costs (no data available in HPS)

  6. Mean costs per patient for statin use and hospitalisation for any vascular event

  7. Overall cost-effectiveness within trial (95% CI) Cost per MVE avoided: £11,000 (£8-16,000) Cost per vascular death avoided: £66,000 (£42-135,000)

  8. Assessing subgroup effects reliably • Analyses in different subgroups indicate: • Similar relative reduction in vascular events • Similar relative reduction in costs of vascular events • Similar absolute difference in statin treatment cost • Hence,cost-effectiveness for subgroups estimated by applying overall treatment effects to placebo event rates and costs observed in each subgroup

  9. Cox model on baseline characteristics used to create 5 multivariate risk groups

  10. Similar relative reduction in first MVE by prior disease and age Baseline SIMVASTATIN PLACEBO Rate ratio & 95% CI (10269) (10267) feature STATIN better PLACEBO better Prior disease Any CHD 21.8% 27.5% No prior CHD CVD 18.7% 23.6% PVD 24.7% 30.5% Diabetes 13.8% 18.6% Age (years) <65 16.9% 22.1% ≥ 65 <70 20.9% 27.2% ≥ 70 23.6% 28.7% 24% SE 3 ALL PATIENTS 19.8% 25.2% reduction (2P<0.00001) 0.4 0.6 0.8 1.0 1.2 1.4

  11. Similar relative reduction in first MVE by LDL & HDL Baseline SIMVASTATIN PLACEBO Rate ratio & 95% CI (10269) (10267) feature STATIN better PLACEBO better LDL Cholesterol (mmol/l) <3.0 17.6% 22.2% ≥ 3.0 <3.5 19.0% 25.7% ≥ 3.5 22.0% 27.2% HDL Cholesterol (mmol/l) <0.9 22.6% 29.9% ≥ 0.9 <1.1 20.0% 25.1% ≥ 1.1 17.0% 20.9% 24% SE 3 ALL PATIENTS 19.8% 25.2% reduction (2P<0.00001) 0.4 0.6 0.8 1.0 1.2 1.4

  12. Similar relative reduction in first MVE by risk group Risk SIMVASTATIN PLACEBO Rate ratio & 95% CI (10269) (10267) group STATIN better PLACEBO better 1 (low risk) 8.3% 11.8% 2 13.9% 18.2% 3 18.4% 24.9% 4 24.5% 29.6% 5 (high risk) 33.8% 41.4% 24% SE 3 ANY OF ABOVE 19.8% 25.2% reduction (2P<0.00001) 0.4 0.6 0.8 1.0 1.2 1.4

  13. Similar relative reduction in costs (£) ofall vascular events by prior disease and age Baseline STATIN PLACEBO feature Prior disease Any CHD 2158 2675 No prior CHD  2 = 0.8 CVD 1281 1641 3 PVD 1866 2563 Diabetes 1076 1445 Age < 65 1572 2066  2 = 0.8 2 65 - 70 1958 2369 > 70 2115 2710 ALL PATIENTS 1819 2319 0.78 (0.73-0.84) 0.4 0.6 0.8 1.0 1.2 1.4

  14. Similar relative reduction in costs (£) of all vascular events by risk group Risk STATIN PLACEBO group 1 (low risk) 784 1219 2 1364 1746  2 = 4.0 3 1773 2120 4 4 2168 2610 5 (high risk) 3000 3903 ALL PATIENTS 1819 2319 0.78 (0.73-0.84) 0.4 0.6 0.8 1.0 1.2 1.4

  15. 2000 1500 1000 500 S S S S S P P P P P 0 Similar absolute difference in statin costs by risk group Statin costs (£) 2 5 4 3 1 Risk group

  16. 2000 1500 1000 500 0 S S S S S P P P P P Similar absolute difference in statin costs by disease and age Statin costs (£) Any CHD ≥ 65 < 70 ≥ 70 No CHD < 65 Age (years) Prior disease

  17. Vascular event cost-savings by risk group 12% 5-yr risk MVE 42% 5-yr risk MVE 100% % Current simvastatin price 50% 25%

  18. Vascular event cost-savings by risk group 12% 5-yr risk MVE 42% 5-yr risk MVE 100% % Current simvastatin price 50% 25%

  19. Vascular event cost-savings by risk group 12% 5-yr risk MVE 42% 5-yr risk MVE 100% % Current simvastatin price 50% 25%

  20. Cost per MVE avoided by risk group 12% 5-yr risk MVE 42% 5-yr risk MVE Overall: £11,000

  21. Cost per vascular death avoided by risk group 12% 5-yr risk MVE 42% 5-yr risk MVE Overall: £66,000

  22. On-going health economic analyses • Extrapolation to effects beyond trial period • Assessment of cost per QALY • Adapt analyses to other countries

  23. CONCLUSIONS: Economic evaluation of HPS • Simvastatin allocation reduced vascular hospitalisation costs by 22% regardless of patient characteristics • Cost-effectiveness is chiefly determined by an individual’s overall risk of vascular events (rather than by single risk factors, such as LDL) • Statin treatment is cost-effective for a wide range of high-risk individuals (and will become increasingly so as statin prices fall)

More Related